Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
Journal Article
|Research
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases
BACKGROUND
Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...
Journal Article
|Research
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health
BACKGROUND
New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...
Journal Article
|Research
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN
BACKGROUND
Dru...
Journal Article
|Research
2024-08-01 • IJTLD OPEN
2024-08-01 • IJTLD OPEN
BACKGROUND
The rate of TB in prison institutions is estimated to be 23 times higher than in the general population. Limited documentation exists regarding TB screening in Tajiki...
Journal Article
|Research
2024-07-01 • IJTLD OPEN
2024-07-01 • IJTLD OPEN
Background
Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...
Journal Article
|Research
2023-05-01 • International Journal of Tuberculosis and Lung Disease
2023-05-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...